100%(51)51 out of 51 people found this document helpful
This preview shows page 1 - 2 out of 2 pages.
NURS 6512WEEK 3: MAIN POSTThe prostate-specific antigen (PSA) is defined as a tumor marker specific to the prostate gland in males. This antigen can be measured in the blood to determine potential risk for prostatecancer. PSA levels below 4 mg/dL are viewed as normal while levels above 10 mg/dL may be indicative of prostate cancer (Dains, Baumann, & Scheibel, 2016). This test is not extremely valid as approximately seventy percent of men with elevated PSA will not actually have a diagnosis of prostate cancer (Biddle, Brasel, Underwood, & Orom, 2015). The PSA test has no specificity as it does not identify high risk cancer that requires treatment versus low risk cancers that would only require monitoring (Fenton, Weyrich, Durbin, Yu, Heejung, & Melnikow, 2018). Authors Fenton, Weyrich, Durbin, Yu, Heejung, and Melnikow (2018) state in their article that while PSA screening has a small potential of decreasing the mortality related to prostate cancer itis also associated with high incidence of false-positive results. False-positive results can lead to